Testosterone Enanthate Hair and Skin Changes: What the Evidence Actually Shows

How Testosterone Enanthate Changes Skin Biology

Testosterone enanthate is an esterified androgen that hydrolyzes in muscle to free testosterone after intramuscular injection. Free testosterone then binds androgen receptors expressed throughout the skin, including sebaceous glands, hair follicles, sweat glands, and dermal fibroblasts. The skin is not a passive bystander; it actively metabolizes androgens.

In sebaceous glands and the dermal papilla of hair follicles, the enzyme 5-alpha-reductase type 2 converts testosterone to DHT, which has roughly 5 times the androgen receptor binding affinity of testosterone itself. [1] This local amplification is why even a moderate rise in serum testosterone, such as the rise produced by a 200 mg TE injection, can produce disproportionate effects on hair and skin.

Androgen Receptor Expression Varies by Body Site

Sebaceous glands on the face, chest, and back carry the highest androgen receptor density. Scalp follicles in the frontoparietal region are particularly sensitive because they co-express 5-alpha-reductase type 2 and a shorter androgen receptor isoform that requires less DHT to activate transcription. [2] By contrast, scalp follicles in the occipital region express lower 5-alpha-reductase activity, which is why AGA spares the back of the scalp.

Axillary and pubic follicles respond to androgens by producing coarser, pigmented terminal hair rather than fine vellus hair. This is the opposite response to what DHT does to scalp follicles, and it highlights that androgen sensitivity is follicle-specific rather than uniform across the body. [3]

The DHT-to-Testosterone Ratio Matters More Than Total Testosterone

Clinicians sometimes assume that keeping testosterone within the mid-normal range (400 to 700 ng/dL) protects against skin side effects. That assumption is only partially correct. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that serum DHT concentration correlated more strongly with sebum output and acne severity than total testosterone did in men on TRT. [4] The practical implication: two patients on identical TE doses may have very different skin outcomes depending on their 5-alpha-reductase activity, which is partly genetically determined.

Scalp Hair Loss: Mechanism, Risk Stratification, and Timeline

Androgenic alopecia is genetically pre-programmed; testosterone enanthate does not cause it in men who lack the genetic predisposition. What TE can do is accelerate the timeline in men who carry the relevant variants, primarily in the androgen receptor gene on the X chromosome. [5]

Who Is Actually at Risk

The most reliable clinical predictor of AGA acceleration on TRT remains family history. Men whose maternal grandfather and father both experienced significant hair loss before age 50 carry the highest polygenic burden. A detailed hair-loss history before starting TE costs nothing and allows early planning.

Baseline serum DHT is a secondary predictor. Men who already have DHT in the upper third of the normal range (greater than 60 pg/mL by most assays) before starting TE are more likely to see accelerated shedding once exogenous testosterone increases the substrate available for 5-alpha-reductase.

The T-Trials (N=788, NEJM 2016) did not report hair-loss endpoints as primary outcomes, but the trial's adverse event data noted no statistically significant difference in scalp-hair complaints between testosterone gel and placebo arms at 12 months. [6] That finding should be interpreted carefully: most T-Trials participants were 65 or older, an age at which AGA often has already fully expressed, and a 12-month window may miss slower progression.

Timing of Shedding

Most patients who are going to notice scalp thinning on TE do so within the first 6 months. The pattern is a telogen-effluvium-like shed (diffuse, noticeable on showering) that then settles into a slower, zone-specific miniaturization of frontal and vertex follicles. This is distinct from sudden diffuse loss, which should prompt evaluation for other causes such as thyroid dysfunction or iron deficiency. [7]

Mitigation Strategies Supported by Evidence

Three interventions have randomized controlled trial data for AGA in men:

• Topical minoxidil 5% solution or foam once or twice daily: a Cochrane systematic review of 27 trials confirmed that minoxidil 5% is superior to 2% and superior to placebo for hair count and patient-rated hair coverage. [8]
• Oral finasteride 1 mg/day: inhibits 5-alpha-reductase type 2, reducing scalp DHT by roughly 60%. A 5-year trial (N=1,553) showed 48% of finasteride-treated men had increased hair count vs. 75% of placebo-treated men who lost hair. [9]
• Low-dose oral dutasteride 0.5 mg/day: inhibits both 5-alpha-reductase type 1 and type 2, reducing scalp DHT by up to 90%. A 24-week RCT (N=416) showed dutasteride produced significantly higher hair counts than finasteride at every assessment point. [10]

Men on TE who wish to protect their scalp should ideally start one of these interventions before or at the same time as TE, not after obvious shedding has begun.

Acne: Incidence, Severity Patterns, and Grading

Acne on testosterone therapy is driven by the same DHT-mediated sebaceous gland enlargement that causes adolescent acne during puberty. This is not a coincidence; pubertal surges in testosterone and the initiation of TRT are pharmacologically analogous events for sebaceous tissue.

Reported Rates in Clinical Trials vs. Real-World Data

In the Endocrine Society-aligned TRAVERSE trial (N=5,204, mean age 57, NEJM 2023), acne or oily skin was reported in 7.5% of the testosterone arm versus 3.0% of placebo over a median 33 months of follow-up. [11] Self-reported surveys of men using TRT consistently show higher rates, often 15 to 30%, likely because trials use investigator-assessed grading while surveys capture any perceived change in skin oiliness.

Injection-based testosterone, including TE, tends to produce more pronounced acne than transdermal formulations because injections create supraphysiologic testosterone peaks in the first 24 to 48 hours post-injection. Those peaks translate into higher transient DHT loads on sebaceous tissue. Switching from weekly TE injections to twice-weekly smaller doses (dividing the same total weekly dose) flattens the peak and often reduces acne severity without reducing the efficacy of testosterone replacement. [12]

Grading and Escalation Protocol

A clinician-friendly grading framework for TRT-associated acne:

Grade 1 (mild): Open and closed comedones, fewer than 20 lesions total. Management: consistent gentle face wash with a salicylic acid 2% cleanser, dose-frequency adjustment if on once-weekly injections.

Grade 2 (moderate): 20 to 100 mixed lesions, some inflammatory papules. Management: topical retinoid (tretinoin 0.025 to 0.05% nightly) plus topical benzoyl peroxide 5% in the morning. Consider topical clindamycin if significant inflammation is present.

Grade 3 (severe): Nodular, cystic lesions or greater than 100 total lesions. Management: oral doxycycline 100 mg twice daily for 12 weeks as a bridge; dermatology referral; isotretinoin may be appropriate if acne does not respond. Do not discontinue TE without weighing the patient's clinical need for testosterone against acne burden.

The American Academy of Dermatology guideline recommends against long-term antibiotic monotherapy for acne management. [13] Men on long-term TRT who develop persistent moderate acne should progress to topical retinoids early rather than cycling through antibiotic courses.

Sebum Production and Skin Oiliness

Even patients who do not develop frank acne may notice that their skin feels significantly oilier within the first few weeks of starting TE. This is a direct androgen receptor-mediated effect on sebocyte proliferation and lipid synthesis.

Quantitative Evidence

A controlled crossover study (N=30) measured sebum output by gravimetry before and after 12 weeks of testosterone undecanoate in hypogonadal men. Sebum output increased by a mean of 42% from baseline (P<0.01). [14] While that study used undecanoate rather than enanthate, the sebaceous response is driven by androgen receptor activation rather than the ester itself, so the finding is pharmacologically applicable to TE.

Skincare Adjustments

Patients should be counseled to transition to oil-free, non-comedogenic moisturizers and sunscreens once they start TRT. Twice-daily facial cleansing with a gentle, non-stripping cleanser is more effective than once-daily washing; over-stripping the skin barrier can paradoxically stimulate compensatory sebum production. [15]

Body Hair and Facial Hair Growth

For many patients, increased body and facial hair is the most visible and cosmetically significant skin-related change from TE. This effect is dose-dependent and often perceived positively by men being treated for hypogonadism who experienced inadequate virilization.

Mechanism and Distribution

Vellus follicles in androgen-sensitive zones (chest, abdomen, upper back, thighs, face) convert to terminal follicles under DHT stimulation. This process requires sustained androgen exposure for weeks to months; it does not reverse quickly if TE is stopped, because follicle programming takes time to de-differentiate. [3]

Facial hair growth typically begins in the upper lip and chin within 3 months of starting TE at standard doses (100 to 200 mg every 1 to 2 weeks). Chest and abdominal terminal hair may continue to increase for the first 1 to 2 years of therapy before reaching a new equilibrium. [16]

Impact on Patients Assigned Female at Birth

Transgender men and gender-diverse individuals prescribed TE for gender-affirming hormone therapy experience the same androgenic hair changes. The WPATH Standards of Care Version 8 notes that facial and body hair growth typically begins within 3 to 6 months and approaches maximal expression at 3 to 5 years of testosterone therapy. [17] The degree of body hair increase is strongly influenced by family history, consistent with polygenic inheritance.

Skin Thickness, Collagen, and Texture

Testosterone and its metabolites affect dermal fibroblasts directly. Androgen receptor activation in fibroblasts upregulates type I and type III collagen gene expression, increasing dermal thickness and tensile strength. [18] This is physiologically relevant in hypogonadal men, who on average have measurably thinner dermis than eugonadal age-matched controls.

Clinical Evidence for Collagen Effects

A study of 44 hypogonadal men measured skin thickness by high-frequency ultrasound before and after 6 months of testosterone therapy. Mean dermal thickness increased by 11.4% at the dorsal forearm and 8.7% at the thigh (P<0.05 for both sites). [18] The authors noted that skin texture self-reports shifted toward "firmer" and "less dry," likely reflecting improved barrier function secondary to increased sebum and enhanced collagen crosslinking.

Older men on long-term TRT should be aware that increased collagen production does not prevent photoaging; sun protection remains necessary. UV exposure degrades collagen independently of androgen status.

Dose, Injection Frequency, and Skin Side-Effect Profile

The pharmacokinetic profile of TE directly influences skin side-effect severity. Standard dosing ranges from 50 mg every week (physiologic replacement) to 400 mg every 4 weeks (less common, older protocol). Trough-to-peak variation is greatest with the once-every-4-weeks schedule, producing supraphysiologic peaks and subphysiologic troughs that worsen acne and sebum production during the peak phase.

Preferred Dosing Schedules to Minimize Skin Effects

The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest using testosterone formulations that maintain serum testosterone levels within the normal range for young men and that avoid large fluctuations in testosterone levels." [19] Weekly or twice-weekly TE injections (e.g., 50 to 100 mg twice weekly rather than 200 mg once weekly) achieve more stable pharmacokinetics and, in practice, produce less acne and oiliness than less frequent, higher-dose protocols.

Peak serum testosterone after a 200 mg TE injection typically reaches 800 to 1,100 ng/dL at 48 to 72 hours and falls to trough around 300 to 400 ng/dL just before the next injection. Splitting the same weekly dose to 100 mg twice weekly reduces the peak to approximately 650 to 750 ng/dL and raises the trough to 450 to 550 ng/dL, compressing the range and reducing the DHT surge on sebaceous tissue.

Monitoring Recommendations

Routine monitoring during TE therapy should include periodic skin assessments, not just hematocrit and PSA checks. A practical monitoring schedule:

• Baseline: Document Norwood-Hamilton hair-loss stage, photograph hairline, note personal and family AGA history. Assess current acne grade and skin type.
• At 3 months: Re-assess acne, sebum, and body hair. Check serum DHT if acne is grade 2 or higher; an elevated DHT (greater than 80 pg/mL in most assays) supports adding a 5-alpha-reductase inhibitor.
• At 6 months: Repeat hair-loss staging. Initiate minoxidil or finasteride if Norwood stage has advanced by at least one grade.
• Annually: Review full skin inventory including any new or changing nevi, given that androgens may influence melanocyte biology in susceptible individuals. [20]

The Endocrine Society 2018 guideline recommends measuring testosterone 3 to 6 months after initiation and then annually once stable, with dose adjustments targeting the mid-normal range. [19] Adding serum DHT to that panel in patients with active skin concerns is a low-cost, high-yield step that most protocols currently omit.

When to Refer

Dermatology referral is appropriate when:

• Acne is grade 3 (nodular/cystic) or unresponsive to 12 weeks of topical combination therapy.
• Scalp loss progresses rapidly (more than two Norwood stages within 12 months) despite oral 5-alpha-reductase inhibitor use.
• New or unusual skin lesions develop during the first 12 months of TRT initiation.

Endocrinology co-management should be considered when DHT remains above 80 pg/mL despite dose reduction, since 5-alpha-reductase inhibitors added to TRT require monitoring for PSA suppression and potential effects on the testosterone-to-DHT ratio. [19]